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Vaccination of piglets at 2 and 3 weeks of
age with Ingelvac PRRSFLEX® EU provides
protection against heterologous field
challenge in the face of homologous
maternally derived antibodies
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Abstract
Background: Due to difficulties in eradicating porcine reproductive and respiratory syndrome (PRRS) linked to
biosecurity challenges, transmission of the virus and the lack of efficient DIVA vaccines, successful control of PRRS
requires a combination of strict management measures and vaccination of both sows and piglets. The present
study aimed to assess the efficacy of a recently developed MLV vaccine (Ingelvac PRRSFLEX® EU) in piglets at 2 and
3-weeks of age in the presence of homologous maternally derived antibodies as the dams were vaccinated with
the same vaccine strain (ReproCyc® PRRS EU).
Methods: The study was carried out on a Hungarian farrow to finish farm naturally infected with PRRSv. The study
was designed as a blind, placebo controlled side by side trial. ORF5 sequence similarity of the vaccine strain and
the resident field strain was 87.8 %. PRRS specific real-time quantitative PCR was performed from serum samples to
measure both the viral load and the frequency of virus positive animals.
Results: At the time of the natural infection observed in the control group at 10–12 weeks of age, the number of
viraemic animals did not increase significantly in the vaccinated group. To understand the infection dynamics,
positive PCR samples with low Ct values were sequenced (ORF5) and the data analysis indicated the circulation of
wild type virus in both groups, however wild type virus was only found in non-vaccinated animals.
Conclusions: Our data indicate that piglets vaccinated at as early as 2 weeks of age with Ingelvac PRRSFLEX® EU were
protected both in terms of proportion of viraemic animals and viraemia levels. It has to be highlighted that these results
were achieved in piglets with high levels of homologous maternally derived antibodies (MDA) at the time of vaccination.
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Background
Porcine reproductive and respiratory syndrome (PRRS)
is one of the most widespread, and economically devas-
tating disease in swine industry. It is characterized by
reproductive losses in breeding herds, increased mortal-
ity in newborn pigs and respiratory disorders in growing
pigs [1, 2].
The disease emerged almost at the same time in Eur-
ope [3] and North America [4], and since then, it has
rapidly spread throughout the world, and become en-
demic in almost every major swine producing country.
PRRS virus (PRRSV) is a member of the Arteriviridae
family within the order of Nidovirales [5]. The relatively
small, enveloped virus has a positive-sense single-stranded
RNA genome of approximately 15.1 kb in length and
encodes 10 ORFs [6–8]. In the last years new ORFs (TF)
and −1/−2 programmed ribosomal frameshift signals were
discovered in ORF1a, expressing two novel proteins,
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nsp2TF and nsp2N [9, 10]. Moreover alternative reading
frames were identified on the structural protein coding re-
gions: ORF2, ORF5 and most recently on ORF7 coding
for GP2a, GP5a and ORF7ap, respectively [11, 12].
Soon after the first isolation, marked genetic differ-
ences were identified between these strains and they
were classified in two distinct genotypes (Type I,
formerly EU, and Type II, formerly NA) [5, 13]. Recent
phylogenetic studies performed on Lithuanian, Belarus-
sian and Russian Type I strains revealed unexpectedly
high degree of variability within this genotype and led to
the definition of four subtypes [14, 15].
The current strategies used to control, or eliminate
PRRS require strict management implications including
the application of strict biosecurity measures, whole
herd depopulation and repopulation, test and removal of
seropositive animals, closure of the breeding herd, and
vaccination [16].
The marked genetic differences observed among vari-
ous PRRSV isolates can have a negative effect on the ef-
ficacy of modified live vaccines (MLV) [17], however the
degree of genetic similarity between the resident strain
and the vaccine does not predict the degree of protec-
tion conferred after vaccination [18].
Previous studies using Type I MLV and a natural ex-
posure of growing pigs to a field strain of the same
genotype reported a reduction of clinical signs, and im-
proved activation of cell mediated immunity in vacci-
nated animals, but the vaccination did not reduce the
incidence of viraemic animals and the levels of viraemia.
The duration of viraemia however was shorter in vacci-
nated piglets [19]. In an other study, performed on
PRRSV exposed pregnant sows using commercially
available attenuated and farm-specific inactivated vac-
cine the authors found significantly lower number of vir-
aemic piglets born to sows of vaccinated groups
compared to mock-vaccinated ones. Their results indi-
cated that both vaccines could be useful tools in the
control of PRRS in the breeding herd [20].
Therapeutic use of a Type II MLV vaccine as an inter-
vention in an acute outbreak was reported to reduce the
duration of viral shedding. Also reduced respiratory dis-
ease and improved production parameters were re-
corded when the challenged-vaccinated animals were re-
infected with a highly virulent challenge strain [21]. In a
recent study the therapeutic, post-infection use of the
same Type II MLV was reported to reduce significantly
the viral shedding as measured by oral fluid analysis and
cumulative PRRSV presence in the air [22].
The objective of the present work was to determine
and compare the efficacy of a recently developed MLV
vaccine (Ingelvac PRRSFLEX® EU) to a mock (PBS)
vaccinated cohort in 2 and 3 weeks old piglets born to
sows mass-vaccinated twice with a homologous MLV
ReproCyc PRRS® EU and assess the possible interference




This study was conducted in on a commercial, farrow to
finish, closed system farm in Hungary. Monitoring over
several years showed an ongoing PRRS wild type strain
circulation on the farm, confirmed by an actual screen-
ing shortly before study initiation. The pre-screening of
the herd was performed as a cross sectional ELISA sero-
profiling and PCR on serum samples obtained from 80
animals (10 samples of pigs at the age of 2, 4, 6, 8, 10,
12, 14, 16 weeks). The results revealed an ongoing field
virus circulation starting in 6-weeks-old animals.
Sequences obtained from the study site over time are in-
cluded in Fig. 4. In total 475 piglets at 2 weeks of age
and 551 piglets at 3 weeks of age were included in the
study. The batches of piglets were divided into a vaccinated
group (Ingelvac PRRSFLEX® EU) and a non-vaccinated
control group (246/229 and 351/200 vaccinated/non-
vaccinated animals in the 2two- and 3-weeks of age
group, respectively). Piglets were vaccinated under the
sow and then at 4 weeks of age transferred to one barn
that was surrounded by fattening units and farrowing
barns. Groups were held in separate rooms and not
commingled until the age of 12-weeks of life. The study
was blinded for treatment and randomized by farrowing
units to prevent cross contamination of non-vaccinated
piglets. The piglets originated from sows and gilts that
were previously vaccinated with ReproCyc® PRRS EU
(Boehringer Ingelheim Vetmedica GmbH, Germany).
Vaccine strain
The Ingelvac PRRSFLEX® EU vaccine strain (PRRS
94881, full genome Gen Bank accession number
KT988004) is attenuated from a field virus first isolated
in 2002 from a farm in Germany with clinical symptoms
of PRRS. The parental strain belongs to the European
Type I, subtype 1 lineage of PRRS viruses. The vaccine
strain shared 87.8 % nucleotide identity in the ORF5
gene with the circulating resident wild type PRRSV
strain.
Treatment
Piglets were vaccinated with one dose of Ingelvac
PRRSFLEX® EU vaccine with a minimum immunizing
dose as indicated on the vaccine label instructions at 2-
weeks of age or 3-weeks of age. Control animals were
administered one dose of vaccine solvent (PBS) without
antigen content. No other vaccinations or treatments
were administered to the animals on at least 3 days be-
fore and after the PRRS vaccine treatment.
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Sample analysis and assessment of viremia and serology
In each group, 20 % of animals were designated at ran-
dom as sample animals for blood collection. Blood sam-
ples were collected pre-vaccination and then weekly in
weeks four to ten after vaccination for the 2 weeks of
age groups and weekly in weeks three to nine after vaccin-
ation in the 3 weeks of age groups. After drawing, blood
samples were allowed to clot at room temperature, were
centrifuged and serum harvested. Serum samples were
held at −80 °C and for serology and qPCR testing,
respectively.
PRRS serology
For ELISA the IDDEX PRRS X3 test was used following
the manufacturer’s instructions (HerdChek* Porcine Re-
productive and Respiratory Syndrome Antibody Test Kit
X3 – IDEXX Laboratories Inc., Westbrook, ME, USA).
Results were reported as negative (ELISA sample to
positive [S/P] ratio of < 0.4) or positive (ELISA S/P ratio
of ≥ 0.4).
PRRS serum qPCR
For detection of PRRS virus RNA a validated TaqMan
probe based quantitative reverse transcription real time
PCR targeting the viral ORF7 was used (bioScreen
EVDMC GmbH, Hannover, Germany). Results were re-
ported as negative (n.d.), positive (not quantifiable, <3.0
log10 genome equivalents (GE)/ml) and quantifiable
log10 GE/mL. A qPCR result of n.d. (not detected) was
assigned a value of 0 log10 GE/mL and a positive qPCR
result was assigned a log10 value of 3.0 GE/mL for stat-
istical purposes.
Sequencing
Serum samples tested positive by qPCR and that
exceeded a virus concentration of 3.0 GE/ml were se-
lected for ORF5 sequence analysis. Sequencing of ORF5
was done by amplifying the respective region of the
PRRSV genome by PCR directly from the samples,
followed by Sanger-sequencing of the purified PCR
product according to Balka et al. [23]. The sequencing
data obtained was aligned with ORF5 sequences of
PRRSV reference strains (i.e. wild type strain circulation
on the farm, vaccine strains of commercially available
vaccines used on the farm) and subsequent calculation
of sequence similarities between the sequences. Se-
quence analysis was done with CLC Main Workbench
v4.1.1.
Phylogenetic analyses were performed using the
CLUSTAL X 1.81 software employing IUB DNA weight
matrix with 0.5 transition ratio. Bootstrap resampling
was carried out on 100 replicate data sets. Phylogenetic




To prove efficacy of a vaccine protection has to be
proven by a challenge with virulent wild type PRRS
virus. A virulent PRRS virus strain was circulating on the
farm before initiation of the study as proven by virus iso-
lation and subsequent sequencing over the past years.
Previous cross sectional screening results performed less
than 4 months before the start of the study showed an
active PRRS circulation in pigs as early as 6 weeks of
age, with a peak at 10 weeks of age (data not shown).
ORF5 sequence similarity of the field strain and the vac-
cine strain was 87.8 %. Field challenge in the study ani-
mals was also controlled by sequencing of PRRS virus
positive blood samples. First signs of a field challenge
occurred at 9 weeks of age in non-vaccinated animals.
Since the study investigation ended at 12-weeks of age
for all animals the peak of field infection might have not
been reached at that time.
Serology
Piglets were tested for PRRS specific antibodies 1 day
before vaccination. In the 2-weeks of age group 92 %
(48/52; Confidence Interval (CI) 95 %: 81.5–97.9) and
96 % (52/54; CI 95 %: 87.3–99.5) of piglets were sero-
positive due to maternally derived antibodies in the vac-
cinated group and the control group, respectively. In the
3-weeks of age group the level of maternal antibodies at
study initiation declined to 89 % (39/44; CI 95 %: 75.4–
96.2) and 80 % (56/70; CI 95 %: 68.7–88.6) of seroposi-
tive piglets in the vaccinated and control group at study
inclusion. In the control group the frequency of sero-
positive pigs continuously and rapidly dropped to 12 %
(6/52; CI 95 %: 4.4–23.4) and 5 % (2/42; CI 95 %: 0.6–
16.2) until the ninth week of life in the 2-weeks of age
group and until the tenth week of life in the 3-weeks of
age group, respectively. In contrast, the vaccinated ani-
mals remained seropositive throughout the study at a
high percentage of animals. In the 2-weeks of age group
at least 80 % (43/54; CI 95 %: 66.5–89.4) of animals were
tested seropositive until the start of the field challenge.
In the initial phase of field challenge the frequency of
seropositive animals dropped to 57 % (31/54; CI 95 %:
43.2–70.8), but quickly recovered after 2 weeks. A simi-
lar pattern was found in the 3-weeks of age vaccinated
group. Again, the frequency of seropositive animals
dropped initially to 59 % (40/68; CI 95 %: 46.2–70.6)
3 weeks post vaccination due to declining maternal anti-
body levels, but recovered to 82 % (58/71; CI 95 %:
70.7–89.9) once vaccination induced antibodies were
produced by the animal itself (Fig. 1).
Due to maternally derived antibodies, piglets were
positive at vaccination with S/P ratios of 1.62 and 1.16 at
2-weeks and 3-weeks of age, respectively. Vaccinated
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animals remained this antibody level with S/P ratios of
1.56 at 9-weeks of age in the group vaccinated at 2-
weeks of age and 1.14 at 10-weeks of age in the group
vaccinated at 3-weeks of age. In contrast, non-
vaccinated animals dropped to S/P ratio levels of 0.18
and 0.31 at 9 and 10-weeks of age, respectively (Fig. 2).
Frequency of viremic animals after vaccination and at
field challenge
The vaccinated group showed up to 15 % (8/54 CI 95 %:
6.6–27.1) PRRS positive animals after vaccination in the
2-weeks of age group, while all non-vaccinated animals
remained qPCR negative. At the time of field challenge
the vaccinated groups both in the 2-weeks of age vacci-
nated group and the 3-weeks of age vaccinated group
stayed at this low level of PRRS positive animals or even
declined (Fig. 3). However, upon field challenge the
non-vaccinated groups started to rapidly increase the
frequency of PRRS positive animals up to 46 % (24/52;
CI 95 %: 32.2–60.5) in the 2-weeks of age group and
40 % (17/42; CI 95 %: 25.6–56.7) in the 3-weeks of age
group. The difference of affected animals between the
vaccinated and control group were highly significant
(p = 0.0026).
Detection of serum viral copies after vaccination and at
field challenge
Low levels of PRRS viraemia was detected by qPCR in
the vaccinated groups shortly after vaccination, while
the control groups remained PRRS virus negative in this
period (Fig. 3). The maximum mean titer, including all





























CP-2woa Vaccine-2woa CP-3woa Vaccine-3woa
Fig. 1 Frequency of seropositive animals vaccinated at 2-weeks of age and 3-weeks of age. Solid curves represent Ingelvac PRRSFLEX EU
vaccinated groups, doted curves represent unvaccinated control groups. Vertical bars represent the 95 % confidence interval. CP, control product
(mock vaccination); woa, weeks of age
Fig. 2 Antibody levels in piglets before and after vaccination. Boxplot of S/P ratios of animals before vaccination and 7-weeks after vaccination.
Whiskers represent the min and max ratio
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5 weeks after vaccination at 0.278 log10 GE/mL. All but
one positive tested animals at all time points before field
challenge showed only non-quantifiable qPCR results.
Field challenge occurred at 9 weeks post vaccination as
indicated by the appearance of the first PRRSV positive
animals in the control group. During the field challenge
the mean titer of the vaccinated group peaked at 0.472
log10 GE/mL in the 2-weeks of age group and 0.46
log10 GE/mL in the 3-weeks of age group, while the
non-vaccinated animals reached 2.23 log10 GE/mL and
1.48 log10 GE/mL in the 2-weeks and 3-weeks of age
groups, respectively. The difference at the end of the
study was highly significant for the 2-weeks of age group
(p < 0.0001) and 3-weeks of age group (p = 0.0006).
Sequence analysis of ORF5 gene
In total 42 PRRS positive serum samples originating
from 30 animals were subjected to ORF5 sequencing
based on quantifiable amounts of genome copies in
them (i.e. >3.0 GE/ml). All sequenced samples were
originating from the time of wild type PRRSV challenge
(Table 1). 37/42 samples belonged to animals of the
non-vaccinated control groups, while only five samples
were found to be suitable for sequencing from the vacci-
nated groups (Fig. 4). Complete ORF5 sequences were
compared to each other, to the sequences of the resident
wild type PRRS strain collected previously, to the Ingel-
vac PRRSFLEX® EU vaccine strain, and a commercially
available MLV strain used previously on the farm. 40/42
strains were identical or very closely related (>98 % simi-



































































































Fig. 3 Frequency of qPCR positive animals and viral load in animals vaccinated at a 2-weeks of age and b 3-weeks of age. Bars represent the per
cent of viremic animals (Error indicators represent the upper 95 % confidence interval), curves represent the mean viral load (log10 GE/ml) over all
animals tested
Table 1 Group assortment of sequenced isolates
Vaccination at 2-weeks of age 3-weeks of age
IVP CP IVP CP
10 weeks of life 1 1 0 1
11 weeks of life 1 8 0 3
12 weeks of life 1 18 2 6
CP control product





















































Fig. 4 (See legend on next page.)
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animal carried a derivative strain of a commercial MLV
strain (previously used in the farm) with 98.4 % se-
quence homology, and from one vaccinated animal the
Ingelvac PRRSFLEX® EU vaccine-like strain with 99.5 %
sequence identity was isolated.
Discussion
The present study aimed to assess the field efficacy of a
recently developed MLV PRRS vaccine (Ingelvac
PRRSFLEX® EU) in piglets at 2 and 3 weeks of age in the
presence of homologous maternally derived antibodies.
At the time of the field challenge infection, observed in
the control group (10–12 weeks of age, WOA), the
number of viraemic animals did not increase in the vac-
cinated group. It has to be highlighted that results were
achieved in piglets with high levels of homologous ma-
ternally derived antibodies at the time of vaccination
since the dams were vaccinated with the same vaccine
strain (ReproCyc® PRRS EU).
The protective effect of the MLV against natural chal-
lenge is either related to the successful induction of neu-
tralizing antibodies (NAs), and/or boost of the cellular
immunity. Previous studies have shown that passive
transfer of NAs can protect pregnant sows from vir-
aemia, transplacental shedding and reproductive failure,
whereas titres higher that 1:32 can confer sterilizing im-
munity in growing pigs [24, 25]. The protection however
will be less effective in case of heterologous challenge
even in the same genotype [17]. The genetic differences
however (usually expressed as ORF5 similarities) between
the immunizing and the challenging strains cannot predict
the degree of the protective immunity conferred [18].
Moreover marked differences have been observed among
PRRSV isolates both in terms of their susceptibility to
neutralization by NAs induced by other strains and also in
their ability to induce NAs that are neutralizing a broad
spectrum of isolates [26].
Other authors found that vaccine efficacy in their
heterologous challenge model was attributed to the abil-
ity of the MLV to boost the cellular immunity by the in-
duction of IFN-γ secreting cells that inversely correlated
with the production of IL-10 by PBMCs [27].
Our results indicate proper efficacy of the vaccine
strain in terms of proportion of viraemic animals as well
as levels of viraemia, however further studies are needed
to assess the neutralization ability and spectrum of the
NAs induced by Ingelvac PRRSFLEX® EU, and it’s ability
to induce specific cellular immunity.
Another critical part of the results was the presence of
relative high amounts of homologous maternal antibodies
at the time of vaccination. Evidence can be found in the
literature proving the negative effect of the MDAs on
the antibody responses after vaccination (reviewed in
[28, 29]). For example, piglets vaccinated in the pres-
ence of MDAs had lower levels of antibody response in
case of Aujeszky disease [30], swine influenza virus [31],
and Mycoplasma hyopneumoniae [32]. On the other
hand, the development of the specific cell mediated im-
munity seems to be less affected or even enhanced by
the MDAs. In a recent study piglets vaccinated at 7 days
of age in the presence of MDAs against Mycoplasma
hyopneumoniae showed an earlier cell mediated immun-
ity even though they failed to show vaccine-induced anti-
body response [33], however results obtained in the case
of other pathogens can not be directly adapted to PRRSV
infection.
Titre dependent interaction between MDAs and vac-
cination has been observed by van Woensel et al. [34],
who observed high proportion of vaccine takes either
at high and low antibody titres, but not at medium ti-
tres. The authors explained this observation by the ef-
fect of opsonization as an alternative mechanism of
PRRSV to enter in the macrophages at high antibody ti-
tres. However this Fc receptor based entry route for
PRRSV has been questioned lately [35]. However it has
to be highlighted, that S/P ratios as measured by ELISA
test in our study do not necessarily correspond to anti-
body titre values and even less to neutralizing antibody
levels.
The partial interference of the MDAs with the vaccin-
ation cannot be excluded in our case as MDA positive
and negative groups were not compared in this study.
Certainly, the vaccinated group developed immunity
allowing to keep the proportion of the viraemic piglets
under 10 % despite the 30–45 % found in the control
group.
In our experiment we found that correct timing of the
vaccination is more dependent on the presumed natural
challenge, than the amount of MDA in the piglets. The
vaccine was able to overcome the suppressing effects of
the homologous MDA and the time frame between the
vaccination and the challenge – observed at 8–10 weeks
of age in the control group – was sufficient to develop
effective immunity and preventing infection. According
to our results, cross sectional seroprofiling and virus de-
tection in the affected age groups is recommended in
(See figure on previous page.)
Fig. 4 ORF5 sequence analysis of qPCR positive samples. Phylogenetic tree based on the ORF 5 nucleotide sequence data of 42 strains obtained
during the study. Bar on the bottom demonstrates the genetic distance. Internal labels represent the bootstrap values of 100 replicates. Arrows
indicate the sequences obtained from the vaccinated groups. Jaszapati named strains are resident viruses of the herd identified during the
indicated years
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order to identify the time of the infection and ensure
ideal timing for vaccination.
Comparative phylogenetic analyses were conducted
after sequencing the ORF5 region of 42 positive samples
with sufficient amounts of viral copies (39 from non-
vaccinated and five from vaccinated group). 40/42
strains were identical or very closely related (>98 % simi-
larity) to the resident wild type strain. The presence of
the wild type virus in the vaccinated group (4 cases)
confirmed the infection pressure by the resident virus
on the farm. Control and vaccinated groups were located
in different rooms in the same barn to prevent the pos-
sible transmission of the MLV strain, but also the rooms
were randomly distributed in the same building to pro-
vide the same environment in terms of virological pres-
sure. One control animal carried a derivative strain of a
commercial vaccine strain with ORF5 98.4 % sequence
identity, and from one vaccinated animal the Ingelvac
PRRSFLEX® EU vaccine strain was isolated.
Conclusions
Summarizing the data we can conclude that piglets vacci-
nated at 2 and 3 weeks of age with Ingelvac PRRSFLEX®
EU were protected against natural infection both in terms
of viraemia levels and proportion of viraemic animals.
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